APPLIED THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.25 USD | -3.41% |
|
-8.01% | +26.87% |
| May. 09 | Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 09 | Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000 | MT |
Presenter SpeechColin Bristow (Analysts)Good afternoon, everyone, and welcome to the UBS Bioph...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companyâs lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Calendar
2024-06-06
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.4
USD
Average target price
11.4
USD
Spread / Average Target
+159.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.87% | 503M | |
| +8.29% | 113B | |
| +10.21% | 106B | |
| +0.41% | 22.27B | |
| -11.90% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.17% | 17.24B | |
| +7.70% | 14.29B | |
| +37.65% | 12.52B |
- Stock Market
- Equities
- APLT Stock
- News Applied Therapeutics, Inc.
- Transcript : Applied Therapeutics, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 02